# OnCo record nct05573126 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05573126/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05573126", "NCT05573126" ;
  schema:name "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer"@en ;
  schema:description "A phase 1/2 trial of EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Ellipses Pharma, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05573126/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05573126> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-01-11" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:drugs <https://onco.cc/drugs/ep0062/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/exemestane/> ;
  onco:companies <https://onco.cc/companies/ellipses-pharma/> .